TechnoBleak Media Inc. (TechnoBleak.com) is an Independent Online News Portal intended to deliver news related to Apps, Technology, Startups, and Gadgets. It is run by writers and co-workers living in different parts of the world. We aim to create high-quality content for our readers who like to read business and technology news & updates. At TechnoBleak, we offer the latest news, breakthroughs, and analysis with emphasis on expert opinion and commentary from the Technology and Startups community.

Category: Gadgets News

Key players operating in the Dravet syndrome treatment market include Epygenix Therapeutics, Inc., Ovid Therapeutics, GW Pharmaceuticals Plc., Takeda Pharmaceutical Company Ltd, Zogenix, Inc, OPKO Health Inc., Biocodex S.A., Biscayne Neurotherapeutics, Inc., and PTC Therapeutics, Inc. Key players in the market are focusing on receiving approval for their novel drugs, from major regulatory bodies such as FDA and European Commission. For instance, in 2017, Biscayne Neurotherapeutics, Inc., received an Orphan Drug designation from the U.S. FDA for its compound BIS-001 indicated for the treatment of Dravet syndrome.

North America is expected to a hold dominant position in the global Dravet syndrome treatment market, owing to increasing initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instances, in 2017, The Dravet Syndrome Foundation—a U.S.-based non-profit organization dedicated to funding the highest caliber research on Dravet syndrome—funded a total amount of US$ 3,600,000 for the development of novel treatment methods for Dravet syndrome. In 2011, Dravet Syndrome Foundation granted an undisclosed amount to U.S.-based OPKO Health, Inc., to support the company’s efforts to develop potential therapeutic agents for the treatment of Dravet syndrome.

Dravet Syndrome Treatment Market Drivers

Increasing research & development activities for the development of novel drugs for Dravet syndrome, and subsequently their approval in key regions such as North America and Europe is expected to fuel growth of the global Dravet syndrome treatment market in near future. In 2017, Epygenix Therapeutics, Inc.—a biopharmaceutical company—received U.S. Food and Drug Administration (FDA) orphan drug designation for its EPX-300, indicated for the treatment of Dravet syndrome. In 2017, Ovid Therapeutics—a U.S.-based biopharmaceutical company—received orphan drug designation for TAK-935/OV935 by U.S. Food and Drug Administration (FDA).

In February 2018, Zogenix Inc. announced FDA approval of breakthrough therapy designation to ZX-008, its Phase III drug for seizures associated with Dravet Syndrome. In 2017, OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc., received orphan drug designation from U.S. FDA for its oligonucleotide-based AntagoNAT (CUR-1916) indicated for the treatment of Dravet Syndrome, and the company also received orphan drug designation for its CUR-1916 from European Commission during the same year. Furthermore, strategic collaborations among key players in market for the development and manufacturing of drugs indicated for treatment of Dravet syndrome is also expected to drive growth of the Dravet syndrome treatment market.

The market in Europe is expected to exhibit significant growth in the Dravet syndrome treatment market, owing to increasing research and development activities being adopted by key players present in the region.

According to guideline published by WHO, vaccine for hepatitis B has to administer within first 24 hour of the birth in order to prevent the hepatitis B infection to infant. Furthermore, increased awareness amongst masses about benefits of hepatitis vaccination would further aid in market growth for the hepatitis vaccine market.

On the basis of regions, hepatitis vaccine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the hepatitis vaccine market, owing to high healthcare spending and availability of robust healthcare infrastructure in the region. According to Centre for Disease Control (CDC) data in 2016, the U.S. had 0.6 cases per 1, 00,000 population. Even though this rate of incidence is low as compared to regions such as Asia Pacific and Africa, still due to highest healthcare spending by U.S. population hepatitis vaccine North America is lucrative market for hepatitis vaccine market.

Hepatitis is one of the most prevalent infectious disease across the globe, it attracted attention from health bodies such as World Health Organization (WHO) due to its severity. Increasing incidence of hepatitis worldwide is estimated to drive growth of the hepatitis vaccine market. According to World Hepatitis Report published in 2017 by WHO, an estimated 325 million people worldwide are living with chronic hepatitis B virus infection (HBV) or hepatitis C virus (HCV) infection. Click to Read More On Hepatitis Vaccine Market

Moreover, an estimated 1.34 million deaths in 2015, were caused due to viral hepatitis. Around 1.75 million people were infected with hepatitis B virus infection (HCV) in 2015. Increasing global population (live births) is another factor driving growth of the hepatitis vaccine market. As per statistics given by the World Population Report published in 2017, world population would surpass mark of 9 billion by 2025 thereby adding more live birth each year.

Asia Pacific has greatest burden of hepatitis (154 million people with hepatitis B) currently as mentioned in World Hepatitis Report, 2017 and it is attractive market for hepatitis market due to the larger population getting infected from the hepatitis. According to the WHO, it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected.

However cost associated with these vaccines in both Hepatitis A and Hepatitis B is matter of concern. Government support is essential for the common affordability of hepatitis vaccine, even though WHO and many national government took initiative to better target hepatitis vaccine. Accessibility of these vaccines is still low especially in remote locations in emerging markets such as Asia Pacific and Africa where increased incidence is observed, which may limit the growth of market. There is attractive opportunity to introduce hepatitis C vaccine as it is one of most prevalent type of hepatitis after hepatitis B and has no vaccine available for it.

North America is expected to account for major share in global anaplastic astrocytoma treatment market, owing to higher awareness about rare diseases such as anaplastic astrocytoma, and also, presence of leading clinical-stage companies in the region. For instance, a study sponsored by Burzynski Research Institute, headquartered at Texas, U.S., is testing antineoplaston therapy (atengenal + astugenal) in clinical trials. The study is currently in phase 2 clinical trials. Furthermore, a clinical trial sponsored by Northwell Health in collaboration with Genentech, Inc. (subsidiary of Roche AG) is testing safety and efficacy of Erlotinib for anaplastic astrocytoma. The study is currently in Phase 1/2. Approval of these pipeline products over the forecast period would boost growth of North America anaplastic astrocytoma treatment market.

Anaplastic Astrocytoma Treatment Market: Driver

Increasing number of drug candidate in pipeline, which may receive approval over the forecast period is expected to drive growth of the global anaplastic astrocytoma treatment market. Currently, there is only a drug, temozolomide (Temodar), approved by U.S. FDA for Anaplastic Astrocytoma. Temodar is an alkylating agent that has been approved for both conditions, newly diagnosed patients as well as refractory anaplastic astrocytoma patients, who have witnessed disease progression in spite of taking drug containing nitrosourea and procarbazine. Click To Read More On Anaplastic Astrocytoma Treatment Market

However, there are multiple products in pipeline for the treatment of anaplastic astrocytoma. For instance, DCC-2618, a drug candidate developed by Deciphera Pharmaceuticals, Inc. is currently in Phase 1 clinical trials. The drug has also been granted orphan drug designation for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) in September 2017.

Moreover, an experimental drug PAC-1 was cleared for the clinical trial of patients with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The trial will determine if the drug candidate is safe to use in combination with a standard chemotherapy drug, temozolomide.

Moreover, the approval of generics for temozolomide will play a vital role in increasing adoption of drug, especially in emerging economies in regions such as Asia Pacific and Latin America. In 2016, FDA approved the Amerigen Pharmaceuticals Limited’s generic version of Temodar. The company’s main facility is in Jiangsu Province, China. Leading global generic players such as Mylan N.V. has also received approval for generic version of Temodar in July 2016. The entry of generic drugs is expected to support growth of the anaplastic astrocytoma treatment market.

The Enzyme Linked Immunosorbent Assay (ELISA) Market is expanding owing to the increasing incidence of chronic diseases mainly in case of infectious diseases, vector borne diseases and cancer. According to the National Cancer Institute, cancer has a major impact on the population of U.S. and across the world. The NCI reports approximately 1,685,210 new cases of cancer were diagnosed in 2016. Also, reports demand for efficient detection tests that can be sufficed with the help of ELISA test kits.

Moreover, increasing demand for cost-effective diagnostic tool is one of the factor aiding the growth of ELISA market, especially in the low and middle income economies. For instance, in October 2017, the Nigerian government and World Health Organization (WHO) launched a campaign to vaccinate around 874,000 people against yellow fever in two states of the country Kwara and Kogi in alliance with the International Coordination Group. The samples of the patients suspected with yellow fever were further tested with the help of ELISA test at the Pasteur Institute in Dakar.

However, availability of alternate immunoassays and cross reactivity projected by these tests can hinder the market growth. Development of cost-effective ELISA tests with improved reliability and accuracy can provide potential opportunity for market players to strategize their growth in the global ELISA market.

Market players are engaged in development of innovative products to maintain leading position in global Enzyme Linked Immunosorbent Assay (ELISA) Market

The key players are developing novel, innovative, and smart products to maintain leading position in the Enzyme Linked Immunosorbent Assay (ELISA) Market. For instance, in January 2017 Illumina, Inc. and Bio?Rad Laboratories, Inc. introduced the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic responses.

On the basis of region, the global Clostridium difficile infection treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to be a dominant market region over the forecast period due to increasing prevalence of Clostridium difficile infection in this region.

Furthermore, European economies are expected to face a decline in Clostridium difficile infection treatment market due to mandatory surveillance, monitoring of antibiotic prescriptions, and reformed compliance with isolation, hand washing, and hygiene protocols. The statistics revealed by Public Health England suggests that Clostridium difficile infection has substantially decreased from 55,498 cases to 13,361 cases between the period of 2007- 2008 and 2013 -2014. Asia pacific is the largest market region due to poor healthcare infrastructure and facilities, and lack of hygiene conditions.

Clostridium difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic acid amplification tests for Clostridium difficile toxin genes or endoscopy.

Limited types of drugs such as metronidazole, fidoxamycin and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in abdominal wall, patients undergo surgery for removal of infected portion. High prevalence of this disease and occasional disease outbreaks in the emerging economies are expected to drive growth of Clostridium Difficile Infection Treatment Market.

Furthermore, development of better diagnostic tools will also drive growth of Clostridium difficile infection treatment market. For instance, Quidel introduced Solana, a FDA approved molecular assay for qualitative Clostridium difficile infection detection. The company claims it as a quick and accurate diagnosis that can process 12 samples in one-shot in 35 min. Moreover, in 2017, Roche developed a Cobas Cdiff nucleic acid test for use on an automated Cobas Liat System, which uses a real time PCR for the detection of Clostridium difficile toxin B. Therefore, therapeutic and diagnostic advancements will enhance Clostridium difficile infection treatment market.

Thrombocytopenia can be inherited or acquired. In 2014, According to a research article published in Professional Med J, 2014, entitled Frequency of Thrombocytopenia, the frequency of thrombocytopenia is higher for people aged 60 years and above, suffering from non-cirrhotic liver disease. However, rampant discovery coupled with the ability to clone thrombopoietin has resulted in new treatment opportunities for clinical manifestation.

Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The most common ineffective production of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia.

Global Thrombocytopenia Treatment MarketDynamics

The thrombocytopenia treatment market is driven by increasing prevalence of thrombocytopenia globally. The risk of developing thrombocytopenia is much higher for chronic Hepatitis C cases. In 2014, according to World Health Organization (WHO), the prevalence of Hepatitis C was lower in Americas and Europe as compared to Africa and Pakistan, where the prevalence of chronic liver disorder was 4-6 % higher than that in Americas and Europe. Liver disease has become a socio economic and global health problem, as 60-80% of the population develops the disease. Furthermore, increasing government support for fast-track approval to discover newer treatments for this disorder and increasing investment in the development of new drugs by biotechnology and pharmaceutical companies are expected to propel growth of the thrombocytopenia treatment market during the forecast period. However, from 2023, thrombocytopenia treatment market is projected to witness a slowdown in growth due to patent expiration and increasing availability of generics of Promacta and MabThera.

Approval of effective and safe drugs for thrombocytopenia treatment to provide momentum to thethrombocytopenia treatment market

More specific treatment plans usually depend on the underlying etiology of thrombocytopenia. In most cases the underlying cause of thrombocytopenia is not known, especially in the case of severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist developed by Shionogi Inc., received approval by Pharmaceuticals and Medical Devices Agency of Japan. Lusutrombopag helped enhance chronic liver disease (CLD) associated with thrombocytopenia for patients scheduled to undergo invasive procedures. Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and stimulates signaling pathways that trigger the proliferation and differentiation of bone marrow cells into megakaryocytes.

According to the National Cancer Institute, cancer is among the leading causes of death worldwide, which accounted for around 14 million new cases and 8.2 million cancer-related deaths in 2012. The number of new cancer cases is projected to rise to 22 million in near future. The major competitors are focused on developing efficient treatment for specific type of cancer which is expected to be a prominent factor to augment the global oncology drugs market.

Oncology drugs and medications have become a blooming business for players in the pharmaceutical industry. Major pharmaceutical companies are focused on manufacturing and development of oncology drug. Market players have oncology drugs in pipeline, which are expected to be in the market as potential medications in near future. Also, the global oncology market is expected to gain a significant traction with the increasing prevalence of cancer.

Top 5 company described for competitive analysis in detail:

Roche is a world leader in oncology, which is engaged in developing new approaches for advanced cancer treatment. Roche operates in two segments, which includes pharmaceuticals and diagnostics with annual sales of US$ 39.1 Bn and US$ 11.5 Bn respectively. Roche is at the forefront of cancer immunotherapy with ten investigational drug candidates currently in the clinical development phase.

Johnson and Johnson operates in three business segments namely consumer, pharmaceutical and medical devices. The business of Johnson & Johnson is conducted by more than 230 operating companies located in 60 countries worldwide. In 2016, the company has invested around US$ 9.1 Bn in research and development activities. Janssen, the pharmaceutical division of J&J registered the oncology drug sales of around US$ 5.9 Bn among the total pharmaceutical therapeutic area sales. Click To Read More On Global Oncology Drugs – Competitive Analysis Market

Pfizer, Inc. develops oncology therapies that provide maximum efficacy while minimizing adverse effects on the patient. The current portfolio of oncology drugs covers a range of cancers. The company studies these therapies alone and in combination with other treatments to improve the lives of cancer patients. Pfizer’s overall strategy is anchored on innovation for developing new medicines and vaccines through collaborations and business relationships which is expected to bolster the oncology drugs market.

A Research Report on EMEA Medium and High Power Motors Market Potential Growth, Share, Demand and Analysis of Key Players – Research Forecasts to (2017 – 2022). The global EMEA Medium and High Power Motors Market research report covers main factors responsible for the development of the global EMEA Medium and High Power Motors Market.

In this report, the global EMEA Medium and High Power Motors market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2022, growing at a CAGR of XX% during the period 2017 to 2022.

EMEA Medium and High Power Motors Worldwide Market research report check out the growth rate and the market value on the basis of market dynamics, growth-inducing factors. The complete knowledge EMEA Medium and High Power Motors Market depends on the most recent industry news, opportunities, and trends. EMEA Medium and High Power Motors Global Market research report provides a clear insight into the persuasive factors that are expected to transform the global market in the near future.

This assessment includes EMEA Medium and High Power Motors industry key vendor’s discussion on the basis of the company’s profiles, summary, market revenue, financial analysis, and opportunities by top geographical regions. The analysis of the industry chain is given to help market players develop business strategies for the future and identify the level of competition across the world.

EMEA Medium and High Power Motors Market report provides an elementary summary of the professional collected with its definition, applications and producing technology. Then, the report explores the EMEA Medium and High Power Motors Market global major business players thoroughly. During this half, the report presents the corporate profile, product specifications, capacity and production.

EMEA Medium and High Power Motors Market Regions Covered in Report: North America, Europe and Asia-Pacific and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

Key Topics Covered in Table of Contents:

– Industry summary of EMEA Medium and High Power Motors Market.

– Market Company manufacturer summary and Profiles.

– The EMEA Medium and High Power Motors market research of Technical information and Manufacturing Plants.

– The EMEA Medium and High Power Motors business analysis of capability, Production, and Revenue.

– Price, Cost and Profit Margin Analysis of EMEA Medium and High Power Motors by Regions, Types, and Manufacturers.

– EMEA Medium and High Power Motors business Consumption Volume,

– EMEA Medium and High Power Motors business Consumption worth and Sale worth Analysis by Regions, Types, Applications.

– Major makers Analysis of EMEA Medium and High Power Motors business.

– Selling Dealer or Distributor Analysis of EMEA Medium and High Power Motors.

– Market Chain Analysis of EMEA Medium and High Power Motors.

– Development analytic thinking of EMEA Medium and High Power Motors Market.

– New Project Investment practicability Analysis of EMEA Medium and High Power Motors.

– A conclusion of the EMEA Medium and High Power Motors Market.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

A Research Report on EMEA Lowboy Semi-trailer Market Potential Growth, Share, Demand and Analysis of Key Players – Research Forecasts to (2017 – 2022). The global EMEA Lowboy Semi-trailer Market research report covers main factors responsible for the development of the global EMEA Lowboy Semi-trailer Market.

In this report, the global EMEA Lowboy Semi-trailer market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2022, growing at a CAGR of XX% during the period 2017 to 2022.

EMEA Lowboy Semi-trailer Worldwide Market research report check out the growth rate and the market value on the basis of market dynamics, growth-inducing factors. The complete knowledge EMEA Lowboy Semi-trailer Market depends on the most recent industry news, opportunities, and trends. EMEA Lowboy Semi-trailer Global Market research report provides a clear insight into the persuasive factors that are expected to transform the global market in the near future.

This assessment includes EMEA Lowboy Semi-trailer industry key vendor’s discussion on the basis of the company’s profiles, summary, market revenue, financial analysis, and opportunities by top geographical regions. The analysis of the industry chain is given to help market players develop business strategies for the future and identify the level of competition across the world.

EMEA Lowboy Semi-trailer Market report provides an elementary summary of the professional collected with its definition, applications and producing technology. Then, the report explores the EMEA Lowboy Semi-trailer Market global major business players thoroughly. During this half, the report presents the corporate profile, product specifications, capacity and production.

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

A Research Report on EMEA Hybrid Adhesives and Hybrid Sealant Market Potential Growth, Share, Demand and Analysis of Key Players – Research Forecasts to (2017 – 2022). The global EMEA Hybrid Adhesives and Hybrid Sealant Market research report covers main factors responsible for the development of the global EMEA Hybrid Adhesives and Hybrid Sealant Market.

In this report, the global EMEA Hybrid Adhesives and Hybrid Sealant market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2022, growing at a CAGR of XX% during the period 2017 to 2022.

EMEA Hybrid Adhesives and Hybrid Sealant Worldwide Market research report check out the growth rate and the market value on the basis of market dynamics, growth-inducing factors. The complete knowledge EMEA Hybrid Adhesives and Hybrid Sealant Market depends on the most recent industry news, opportunities, and trends. EMEA Hybrid Adhesives and Hybrid Sealant Global Market research report provides a clear insight into the persuasive factors that are expected to transform the global market in the near future.

This assessment includes EMEA Hybrid Adhesives and Hybrid Sealant industry key vendor’s discussion on the basis of the company’s profiles, summary, market revenue, financial analysis, and opportunities by top geographical regions. The analysis of the industry chain is given to help market players develop business strategies for the future and identify the level of competition across the world.

EMEA Hybrid Adhesives and Hybrid Sealant Market report provides an elementary summary of the professional collected with its definition, applications and producing technology. Then, the report explores the EMEA Hybrid Adhesives and Hybrid Sealant Market global major business players thoroughly. During this half, the report presents the corporate profile, product specifications, capacity and production.

EMEA Hybrid Adhesives and Hybrid Sealant Market Regions Covered in Report: North America, Europe and Asia-Pacific and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

– A conclusion of the EMEA Hybrid Adhesives and Hybrid Sealant Market.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.